DiagnosTear

Screening and Monitoring Kit for Dry Eye Syndrome

Health Tech & Life Sciences
Public on CSE on Dec 2024

Company Overview

Snapshot

Founded in September 2013 by Eran Eilat, DiagnosTear operates with 1-10 employees. The company has raised $4.58 million across 5 funding rounds and went public on the CSE in December 2024.

Business overview

DiagnosTear specializes in developing technology for the diagnosis and treatment of dry eye syndrome. The company's core product, the TeaRx assay, is designed to facilitate diagnosis, treatment, and monitoring by analyzing specific parameters in tear fluid. This assay uses reagents that create color reactions upon contact with tear film, enabling a semi-quantitative assessment of defining parameters. DiagnosTear serves healthcare providers and clinics globally, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices.

Strategic signal

In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform for needle-free blood diagnostics. This strategic move signals the company's expansion beyond its core dry eye syndrome diagnostics into broader, non-invasive diagnostic technologies, potentially opening new market opportunities and enhancing its product portfolio for investors.

Company Intelligence Q&A

What was a significant recent development for DiagnosTear?
In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform, enabling needle-free blood diagnostics.
What were the results of DiagnosTear's recent clinical study?
In July 2026, DiagnosTear announced interim clinical study results demonstrating excellent correlation between its TeaRx Red Eye diagnostic and quantitative ELISA testing.
When did DiagnosTear go public?
DiagnosTear went public on the CSE in December 2024.
What was a key collaboration announced by DiagnosTear in late 2025?
In November 2025, DiagnosTear Technologies announced the initiation of a collaboration with LV Prasad Eye Institute for advancing the clinical validation of its TeaRx Red Eye Diagnostic Test.
What regulatory approvals did DiagnosTear receive in early 2026?
In February 2026, DiagnosTear announced regulatory approvals in France and the initiation of a study with AlyaTec for TeaRx Red Eye.

External links